U.S. markets closed

Enveric Biosciences, Inc. (ENVB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.2200-0.0900 (-2.09%)
At close: 04:00PM EDT
4.3500 +0.13 (+3.08%)
After hours: 07:51PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Previous Close4.3100
Bid4.2500 x 2200
Ask4.5000 x 1200
Day's Range4.2000 - 4.4996
52 Week Range4.2000 - 112.5000
Avg. Volume446,868
Market Cap6.645M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ENVB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Enveric Biosciences, Inc.
    Analyst Report: Salesforce, Inc.Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more

    Enveric Biosciences Files Provisional Patent for Cannabinoid + Celecoxib Conjugate EV104 after Successful Synthesis

    By Alan Hatfield Neuroscience company Enveric Biosciences (NASDAQ: ENVB) announced the creation of EV104a and EV104b for the potential treatment of Osteoarthritis and other pain indications. Known as the […]

  • Market Exclusive

    Cannabis Sector Weekly Roundup

    Key Takeaways: Trulieve, TerrAscend, and Verano Holdings amongst Top Cannabis Gainers for the Week. Awakn Findings from Phase II A/B KARE Study to Be Published In American Journal of Psychiatry; Awakn to Participate at the Wonderland: Miami Conference. FDA Authorizes IND for Sponsored Feasibility Study Using Kernel’s Flow Technology – Cybin Launches EMBARK Psychedelic Facilitator […] The post Cannabis Sector Weekly Roundup appeared first on Market Exclusive.

  • Exec Edge

    Enveric Biosciences on the Merger with MagicMed

    By Exec Edge Editorial Staff Exec Edge: How did the merger between Enveric and MagicMed come about? ​​Enveric had been looking to complement their existing product development activities, which are focused on physical symptoms, with a platform of novel psychedelics that addresses the large mental health challenges related to CNS indications such as Cancer Related […]